Table 1 Clinicopathological characteristics for patients who received temozolomide
Frozen tissue | FFPE samples | ||||
|---|---|---|---|---|---|
Total (200) | The cohort A (86) | The cohort B (49) | The validation cohort (65) | ||
Age (years) | Median (range) | 44 (17–79) | 43 (19–72) | 46 (24–79) | 45 (17–69) |
Age ≥ 45 | 100 (50%) | 41 (48%) | 26 (53%) | 33 (51%) | |
Age < 45 | 100 (50%) | 45 (52%) | 23 (47%) | 32 (49%) | |
Gender | Male | 126 (63%) | 54 (63%) | 33 (67%) | 39 (60%) |
Female | 74 (37%) | 32 (37%) | 16 (33%) | 26 (40%) | |
KPS score | KPS ≥ 80 | 103 (52%) | 44 (51%) | 26 (53%) | 33 (51%) |
KPS < 80 | 87 (44%) | 37 (43%) | 21 (43%) | 29 (45%) | |
N/A | 10 (5%) | 5 (6%) | 2 (4%) | 3 (5%) | |
WHO grade | III | 81 (41%) | 35 (41%) | 24 (49%) | 22 (34%) |
IV | 119 (60%) | 51 (59%) | 25 (51%) | 43 (66%) | |
WHO 2016 classification | Anaplastic Oligo, IDH-mutant, 1p/19q codeletion | 8 (4%) | 3 (3%) | 3 (6%) | 2 (3%) |
Anaplastic Astro, IDH-mutant | 34 (17%) | 21 (24%) | 8 (16%) | 5 (8%) | |
Anaplastic Astro, IDH-wildtype | 30 (15%) | 11 (13%) | 13 (27%) | 6 (9%) | |
Glioblastoma, IDH-mutant | 28 (14%) | 11 (13%) | 6 (12%) | 11 (17%) | |
Glioblastoma, IDH-wildtype | 84 (42%) | 36 (42%) | 18 (37%) | 30 (46%) | |
Anaplastic Astro, NOS a | 9 (5%) | 2 (2%) | 0 (0%) | 7 (0%) | |
Glioblastoma, NOSa | 7 (4%) | 2 (2%) | 1 (2%) | 4 (17%) | |
1p19q codeletion | Codel | 8 (4%) | 3 (3%) | 3 (6%) | 2 (3%) |
Non-codel | 192 (96%) | 83 (97%) | 46 (94%) | 63 (97%) | |
IDH1/2 mutation | Mutation | 70 (35%) | 35 (41%) | 17 (35%) | 18 (28%) |
Wildtype | 114 (57%) | 47 (55%) | 31 (63%) | 36 (55%) | |
N/A | 16 (8%) | 4 (5%) | 1 (2%) | 11 (17%) | |
